Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Dec 05 04:00PM ET
1.41
Dollar change
-0.09
Percentage change
-6.00
%
Index- P/E- EPS (ttm)-0.21 Insider Own52.22% Shs Outstand12.85M Perf Week-14.55%
Market Cap18.12M Forward P/E- EPS next Y- Insider Trans0.10% Shs Float6.14M Perf Month5.22%
Income-2.74M PEG- EPS next Q-0.02 Inst Own0.35% Short Float2.24% Perf Quarter-
Sales0.00M P/S- EPS this Y- Inst Trans- Short Ratio0.37 Perf Half Y-
Book/sh0.26 P/B5.44 EPS next Y- ROA-92.10% Short Interest0.14M Perf Year-
Cash/sh0.25 P/C5.63 EPS next 5Y- ROE-375.74% 52W Range1.22 - 4.00 Perf YTD-45.77%
Dividend Est.- P/FCF- EPS past 5Y- ROI-82.26% 52W High-64.75% Beta-
Dividend TTM- Quick Ratio2.84 Sales past 5Y0.00% Gross Margin- 52W Low15.57% ATR (14)0.24
Dividend Ex-Date- Current Ratio2.84 EPS Y/Y TTM-207.94% Oper. Margin- RSI (14)42.58 Volatility9.78% 18.57%
Employees3 Debt/Eq0.04 Sales Y/Y TTM- Profit Margin- Recom1.00 Target Price9.00
Option/ShortNo / Yes LT Debt/Eq0.00 EPS Q/Q-235.39% Payout- Rel Volume0.25 Prev Close1.50
Sales Surprise- EPS Surprise0.00% Sales Q/Q- EarningsNov 27 Avg Volume367.67K Price1.41
SMA20-12.69% SMA50-6.27% SMA200-11.98% Trades Volume93,561 Change-6.00%
Kairos Pharma Ltd. is a clinical-stage biopharmaceutical company, which engages in the development of novel and transformative drug therapies to treat cancer. It focuses on the research and development of immunotherapies for oncology. The company was founded by John S. Yu on June 17, 2013 and is headquartered in Los Angeles, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Murali RamachandranVP of Research and DevelopmentNov 25 '24Buy1.59200318133,057Nov 25 08:30 PM
Samuelson DougChief Financial OfficerNov 22 '24Buy1.502,5003,75060,796Nov 25 06:03 AM
Yu John SCEO and ChairmanNov 20 '24Buy1.444,0005,7605,341,837Nov 21 09:53 PM